​
​

REGENXBIO (RGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RGNX Stock Forecast

REGENXBIO stock forecast is as follows: an average price target of $32.00 (represents a 215.27% upside from RGNX’s last price of $10.15) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

RGNX Price Target

The average price target for REGENXBIO (RGNX) is $32.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $18.00. This represents a potential 215.27% upside from RGNX's last price of $10.15.

RGNX Analyst Ratings

Buy

According to 6 Wall Street analysts, REGENXBIO's rating consensus is 'Buy'. The analyst rating breakdown for RGNX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

REGENXBIO Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Judah FrommerMorgan Stanley$22.00$11.1497.49%116.75%
Oct 10, 2024Danielle BrillRaymond James$18.00$9.1995.97%77.34%
Sep 05, 2024Yi ChenH.C. Wainwright$39.00$11.38242.86%284.24%
Jun 24, 2024Annabel SamimyStifel Nicolaus$40.00$12.79212.74%294.09%
Jun 07, 2024Paul ChoiGoldman Sachs$38.00$13.76176.16%274.38%
May 15, 2024Yi ChenH.C. Wainwright$38.00$15.80140.51%274.38%
Mar 11, 2024Yi ChenH.C. Wainwright$36.00$22.8557.55%254.68%
Mar 08, 2024Luca IssiRBC Capital$35.00$22.7553.85%244.83%
Row per page
Go to

The latest REGENXBIO stock forecast, released on Nov 15, 2024 by Judah Frommer from Morgan Stanley, set a price target of $22.00, which represents a 97.49% increase from the stock price at the time of the forecast ($11.14), and a 116.75% increase from RGNX last price ($10.15).

REGENXBIO Price Target by Period

1M3M12M
# Anlaysts138
Avg Price Target$22.00$26.33$33.25
Last Closing Price$10.15$10.15$10.15
Upside/Downside116.75%159.41%227.59%

In the current month, the average price target of REGENXBIO stock is $22.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 116.75% increase as opposed to REGENXBIO's last price of $10.15. This month's average price target is down -16.45% compared to last quarter, and down -33.83% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 10, 2024Raymond JamesBuyBuyHold
Sep 04, 2024H.C. WainwrightBuyBuyHold
Aug 05, 2024Goldman SachsUnderperformUnderperformHold
Aug 05, 2024H.C. WainwrightBuyBuyHold
Jun 20, 2024RBC CapitalOutperformOutperformHold
Jun 07, 2024H.C. WainwrightBuyBuyHold
Jun 07, 2024Goldman Sachs-BuyInitialise
May 15, 2024WedbushBuyBuyHold
May 15, 2024H.C. WainwrightBuyBuyHold
Apr 12, 2024WedbushBuyBuyHold
Row per page
Go to

REGENXBIO's last stock rating was published by Raymond James on Oct 10, 2024. The company gave RGNX a "Buy" rating, the same as its previous rate.

REGENXBIO Financial Forecast

REGENXBIO Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$22.21M$28.91M$19.98M$19.14M$31.34M$26.51M$32.65M$22.22M-$30.77M$22.04M$18.88M$21.45M$98.91M$16.57M$17.64M$11.77M$14.70M$7.88M$884.00K$132.39M$455.00K
Avg Forecast$82.88M$69.65M$119.84M$20.68M$23.46M$23.63M$22.97M$23.52M$34.01M$26.14M$34.50M$31.22M$37.45M$30.81M$28.31M$27.22M$427.83M$33.17M$21.17M$18.59M$26.31M$21.45M$20.46M$19.62M$39.67M$7.46M$22.61M$854.20K$43.55M$421.71K
High Forecast$100.48M$84.45M$145.30M$25.29M$26.93M$24.00M$22.97M$23.52M$50.11M$26.65M$41.84M$37.85M$45.41M$30.81M$28.31M$27.22M$427.83M$33.17M$21.17M$18.59M$26.31M$21.45M$20.46M$19.62M$39.67M$7.46M$22.61M$1.03M$52.26M$506.05K
Low Forecast$58.48M$49.15M$84.56M$16.07M$16.22M$23.26M$22.97M$23.52M$24.82M$25.63M$24.35M$22.03M$26.43M$30.81M$28.31M$27.22M$427.83M$33.17M$21.17M$18.59M$26.31M$21.45M$20.46M$19.62M$39.67M$7.46M$22.61M$683.36K$34.84M$337.36K
# Analysts11146333633344443399999988810720
Surprise %--------0.65%1.11%0.58%0.61%0.84%0.86%1.15%0.82%-0.93%1.04%1.02%0.82%4.61%0.81%0.90%0.30%1.97%0.35%1.03%3.04%1.08%

REGENXBIO's average Quarter revenue forecast for Mar 24 based on 3 analysts is $23.52M, with a low forecast of $23.52M, and a high forecast of $23.52M. RGNX's average Quarter revenue forecast represents a 5.91% increase compared to the company's last Quarter revenue of $22.21M (Dec 23).

REGENXBIO EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146333633344443399999988810720
EBITDA--------$-63.90M$-64.90M$-73.11M$-66.09M$-57.69M$-67.48M$-59.74M$-68.84M$313.60M$-48.87M$-49.07M$-41.50M$-37.62M$10.96M$-32.13M$-38.04M$-26.93M$-32.88M$163.00K$-30.68M$105.07M$-21.44M
Avg Forecast$-54.13M$-45.50M$-78.28M$-13.51M$-15.33M$-15.44M$-15.01M$-38.30M$-22.22M$-17.07M$-22.54M$-40.97M$-10.07M$-20.97M$-19.27M$-43.82M$-291.11M$-22.57M$-14.41M$-44.10M$-17.90M$-14.59M$-13.92M$-28.86M$-26.99M$-5.07M$-15.39M$-29.61M$-29.63M$-19.75M
High Forecast$-38.20M$-32.10M$-55.23M$-10.50M$-10.59M$-15.20M$-15.01M$-30.64M$-16.21M$-16.74M$-15.90M$-32.77M$-8.06M$-20.97M$-19.27M$-35.05M$-291.11M$-22.57M$-14.41M$-35.28M$-17.90M$-14.59M$-13.92M$-23.09M$-26.99M$-5.07M$-15.39M$-23.69M$-23.71M$-15.80M
Low Forecast$-65.64M$-55.16M$-94.91M$-16.52M$-17.59M$-15.68M$-15.01M$-45.97M$-32.73M$-17.41M$-27.33M$-49.16M$-12.09M$-20.97M$-19.27M$-52.58M$-291.11M$-22.57M$-14.41M$-52.92M$-17.90M$-14.59M$-13.92M$-34.63M$-26.99M$-5.07M$-15.39M$-35.54M$-35.56M$-23.70M
Surprise %--------2.88%3.80%3.24%1.61%5.73%3.22%3.10%1.57%-1.08%2.17%3.41%0.94%2.10%-0.75%2.31%1.32%1.00%6.48%-0.01%1.04%-3.55%1.09%

4 analysts predict RGNX's average Quarter EBITDA for Mar 22 to be $-43.82M, with a high of $-35.05M and a low of $-52.58M. This is -113.97% lower than REGENXBIO's previous annual EBITDA (Dec 21) of $313.60M.

REGENXBIO Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146333633344443399999988810720
Net Income--------$-62.89M$-61.87M$-72.06M$-69.95M$-59.94M$-79.92M$-73.83M$-76.72M$307.02M$-58.41M$-57.64M$-50.14M$-46.24M$8.79M$-33.76M$-40.04M$-26.46M$-34.58M$-1.46M$-32.23M$104.24M$-21.99M
Avg Forecast$-6.73M$-13.82M$39.83M$-59.54M$-57.15M$-57.01M$-65.61M$-43.19M$-64.53M$-74.00M$-60.28M$-46.19M$-9.90M$-74.48M$-71.09M$-49.40M$389.25M$-52.26M$-56.42M$-53.27M$-56.22M$-50.46M$-44.95M$-30.37M$-33.65M$-36.13M$-29.35M$-31.10M$108.41M$-20.26M
High Forecast$-4.15M$-8.53M$50.83M$-52.65M$-49.50M$-35.19M$-40.50M$-34.55M$-59.45M$-45.68M$-37.21M$-36.95M$-7.92M$-74.48M$-71.09M$-39.52M$389.25M$-52.26M$-56.42M$-42.62M$-56.22M$-50.46M$-44.95M$-24.30M$-33.65M$-36.13M$-29.35M$-24.88M$130.09M$-16.21M
Low Forecast$-8.59M$-17.63M$24.58M$-66.43M$-61.20M$-72.76M$-83.73M$-51.83M$-70.12M$-94.44M$-76.93M$-55.43M$-11.88M$-74.48M$-71.09M$-59.29M$389.25M$-52.26M$-56.42M$-63.93M$-56.22M$-50.46M$-44.95M$-36.45M$-33.65M$-36.13M$-29.35M$-37.32M$86.73M$-24.31M
Surprise %--------0.97%0.84%1.20%1.51%6.06%1.07%1.04%1.55%0.79%1.12%1.02%0.94%0.82%-0.17%0.75%1.32%0.79%0.96%0.05%1.04%0.96%1.09%

REGENXBIO's average Quarter net income forecast for Mar 22 is $-49.40M, with a range of $-59.29M to $-39.52M. RGNX's average Quarter net income forecast represents a -116.09% decrease compared to the company's last Quarter net income of $307.02M (Dec 21).

REGENXBIO SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146333633344443399999988810720
SG&A--------$19.08M$23.08M$23.70M$22.63M$21.21M$20.92M$20.83M$22.32M$22.04M$21.03M$18.43M$17.84M$17.57M$15.86M$15.55M$14.90M$14.49M$12.41M$13.34M$11.56M$8.41M$6.67M
Avg Forecast$62.81M$52.79M$90.82M$15.67M$17.78M$17.91M$17.41M$12.56M$25.78M$19.81M$26.15M$13.44M$5.42M$23.35M$21.46M$14.37M$324.24M$25.14M$16.05M$14.09M$19.94M$16.25M$15.51M$11.30M$30.06M$5.65M$17.14M$647.38K$8.74M$319.60K
High Forecast$76.15M$64.00M$110.12M$19.16M$20.41M$18.19M$17.41M$15.08M$37.97M$20.20M$31.71M$16.12M$6.50M$23.35M$21.46M$17.25M$324.24M$25.14M$16.05M$14.09M$19.94M$16.25M$15.51M$13.56M$30.06M$5.65M$17.14M$776.85K$10.49M$383.52K
Low Forecast$44.32M$37.25M$64.08M$12.18M$12.29M$17.63M$17.41M$10.05M$18.81M$19.42M$18.45M$10.75M$4.34M$23.35M$21.46M$11.50M$324.24M$25.14M$16.05M$14.09M$19.94M$16.25M$15.51M$9.04M$30.06M$5.65M$17.14M$517.90K$7.00M$255.68K
Surprise %--------0.74%1.17%0.91%1.68%3.91%0.90%0.97%1.55%0.07%0.84%1.15%1.27%0.88%0.98%1.00%1.32%0.48%2.20%0.78%17.85%0.96%20.86%

REGENXBIO's average Quarter SG&A projection for Mar 24 is $12.56M, based on 3 Wall Street analysts, with a range of $10.05M to $15.08M. The forecast indicates a -34.15% fall compared to RGNX last annual SG&A of $19.08M (Dec 23).

REGENXBIO EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11146333633344443399999988810720
EPS--------$-1.43$-1.41$-1.66$-1.61$-1.38$-1.85$-1.71$-1.79$7.18$-1.37$-1.36$-1.20$-1.24$0.24$-0.91$-1.08$-0.72$-0.94$-0.04$-0.89$3.30$-0.82
Avg Forecast$-0.13$-0.27$0.78$-1.17$-1.13$-1.12$-1.29$-1.26$-1.27$-1.46$-1.19$-1.42$-1.28$-1.47$-1.40$-1.54$7.69$-1.03$-1.12$-1.28$-1.11$-1.00$-0.89$-0.84$-0.67$-0.71$-0.58$-0.86$1.04$-0.70
High Forecast$-0.08$-0.17$1.00$-1.04$-0.97$-0.69$-0.80$-0.78$-1.17$-0.90$-0.73$-0.88$-0.79$-1.47$-1.40$-1.54$7.69$-1.03$-1.12$-1.28$-1.11$-1.00$-0.89$-0.84$-0.67$-0.71$-0.58$-0.86$1.25$-0.56
Low Forecast$-0.17$-0.35$0.48$-1.31$-1.20$-1.43$-1.65$-1.61$-1.38$-1.86$-1.51$-1.81$-1.64$-1.47$-1.40$-1.54$7.69$-1.03$-1.12$-1.28$-1.11$-1.00$-0.89$-0.84$-0.67$-0.71$-0.58$-0.86$0.83$-0.84
Surprise %--------1.13%0.97%1.40%1.13%1.08%1.26%1.22%1.16%0.93%1.33%1.22%0.94%1.12%-0.24%1.02%1.29%1.08%1.32%0.07%1.03%3.17%1.17%

According to 4 Wall Street analysts, REGENXBIO's projected average Quarter EPS for Mar 22 is $-1.54, with a low estimate of $-1.54 and a high estimate of $-1.54. This represents a -121.44% decrease compared to RGNX previous annual EPS of $7.18 (Dec 21).

REGENXBIO Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PASGPassage Bio$0.47$6.001176.60%Buy
ANTXAN2 Therapeutics$1.00$8.75775.00%Buy
QUREuniQure$6.18$53.67768.45%Buy
FDMT4D Molecular Therapeutics$8.32$41.00392.79%Buy
RCKTRocket Pharmaceuticals$13.66$45.20230.89%Buy
PLRXPliant Therapeutics$12.32$39.71222.32%Buy
RGNXREGENXBIO$10.15$32.00215.27%Buy
DAWNDay One Biopharmaceuticals$13.01$38.80198.23%Buy
STOKStoke Therapeutics$11.88$30.60157.58%Buy
KZRKezar Life Sciences$7.39$17.50136.81%Buy
IMCRImmunocore$31.05$70.75127.86%Buy
REPLReplimune Group$10.77$24.20124.70%Buy
MIRMMirum Pharmaceuticals$41.42$57.2538.22%Buy
RNAAvidity Biosciences$41.35$54.5031.80%Buy
CRNXCrinetics Pharmaceuticals$53.70$70.1430.61%Buy
PTGXProtagonist Therapeutics$40.39$50.0023.79%Buy
RVMDRevolution Medicines, Inc. Warrant$54.24$60.6311.78%Buy

RGNX Forecast FAQ

Is REGENXBIO a good buy?

Yes, according to 6 Wall Street analysts, REGENXBIO (RGNX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of RGNX's total ratings.

What is RGNX's price target?

REGENXBIO (RGNX) average price target is $32 with a range of $18 to $40, implying a 215.27% from its last price of $10.15. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will REGENXBIO stock go up soon?

According to Wall Street analysts' prediction for RGNX stock, the company can go up by 215.27% (from the last price of $10.15 to the average price target of $32), up by 294.09% based on the highest stock price target, and up by 77.34% based on the lowest stock price target.

Can REGENXBIO stock reach $20?

RGNX's average twelve months analyst stock price target of $32 supports the claim that REGENXBIO can reach $20 in the near future.

What is REGENXBIO's current price target trend?

1 Wall Street analyst forecast a $22 price target for REGENXBIO (RGNX) this month, up 116.75% from its last price of $10.15. Compared to the last 3 and 12 months, the average price target increased by 159.41% and increased by 227.59%, respectively.

What are REGENXBIO's analysts' financial forecasts?

REGENXBIO's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $93.59M (high $97.42M, low $85.98M), average EBITDA is $-84.074M (high $-71.44M, low $-94.236M), average net income is $-223M (high $-160M, low $-270M), average SG&A $65.67M (high $71.08M, low $57.39M), and average EPS is $-4.798 (high $-3.242, low $-5.892). RGNX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $293.05M (high $355.52M, low $208.26M), average EBITDA is $-191M (high $-136M, low $-232M), average net income is $-40.259M (high $-14.506M, low $-68.066M), average SG&A $222.09M (high $269.44M, low $157.83M), and average EPS is $-0.792 (high $-0.286, low $-1.34).

Did the RGNX's actual financial results beat the analysts' financial forecasts?

Based on REGENXBIO's last annual report (Dec 2023), the company's revenue was $90.24M, which missed the average analysts forecast of $125.87M by -28.31%. Apple's EBITDA was $-268M, beating the average prediction of $-103M by 160.83%. The company's net income was $-263M, beating the average estimation of $-245M by 7.55%. Apple's SG&A was $88.49M, beating the average forecast of $85.17M by 3.90%. Lastly, the company's EPS was $-6.02, beating the average prediction of $-5.334 by 12.85%. In terms of the last quarterly report (Dec 2023), REGENXBIO's revenue was $22.21M, missing the average analysts' forecast of $34.01M by -34.69%. The company's EBITDA was $-63.903M, beating the average prediction of $-22.216M by 187.64%. REGENXBIO's net income was $-62.889M, missing the average estimation of $-64.534M by -2.55%. The company's SG&A was $19.08M, missing the average forecast of $25.78M by -25.98%. Lastly, the company's EPS was $-1.43, beating the average prediction of $-1.27 by 12.57%